Corient Private Wealth LLC Has $16.90 Million Stock Position in Revvity, Inc. (NYSE:RVTY)

Corient Private Wealth LLC cut its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 151,374 shares of the company's stock after selling 5,856 shares during the period. Corient Private Wealth LLC owned 0.12% of Revvity worth $16,895,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Janus Henderson Group PLC raised its position in shares of Revvity by 1.7% in the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company's stock valued at $809,332,000 after buying an additional 108,401 shares in the last quarter. State Street Corp raised its position in shares of Revvity by 0.3% in the third quarter. State Street Corp now owns 5,180,169 shares of the company's stock valued at $661,767,000 after buying an additional 17,832 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Revvity by 0.9% in the third quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company's stock valued at $364,569,000 after buying an additional 25,078 shares in the last quarter. EdgePoint Investment Group Inc. raised its position in shares of Revvity by 34.6% in the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock valued at $343,108,000 after buying an additional 690,534 shares in the last quarter. Finally, RGM Capital LLC raised its position in shares of Revvity by 3.2% in the third quarter. RGM Capital LLC now owns 980,858 shares of the company's stock valued at $125,305,000 after buying an additional 30,000 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target for the company in a research report on Friday, December 13th. Raymond James reissued an "outperform" rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp lifted their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Barclays lifted their price objective on shares of Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein cut shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $136.25.

Revvity Trading Up 0.2 %

Shares of Revvity stock traded up $0.20 during trading on Friday, hitting $107.18. The company's stock had a trading volume of 1,281,291 shares, compared to its average volume of 850,133. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. Revvity, Inc. has a 52 week low of $97.32 and a 52 week high of $129.50. The stock has a market cap of $12.88 billion, a price-to-earnings ratio of 48.50, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06. The stock has a 50-day moving average price of $116.44 and a two-hundred day moving average price of $117.54.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the previous year, the business earned $1.25 EPS. Equities research analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.26%. Revvity's dividend payout ratio is 12.67%.

Insider Buying and Selling

In related news, insider Joel S. Goldberg sold 15,170 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.